open access

Vol 10, Supp. C (2014)
Case report
Published online: 2014-08-29
Get Citation

The perennial natural history of castration-resistant prostate cancer in the patient treated with docetaxel, cabazitaxel and abiraterone acetate

Anna Wrona, Elżbieta Senkus-Konefka

open access

Vol 10, Supp. C (2014)
CASE REPORT
Published online: 2014-08-29

Abstract

Prostate cancer is the second most frequently diagnosed cancer of men in Poland. There are two well-established primary therapeutic modalities to manage patients with early and locally advanced prostate cancer: surgical treatment and radiotherapy. Hormonal therapy is mainly used in advanced disease. The state of castration-resistant prostate cancer remains still the main therapeutic challenge. In this clinical scenario available therapeutic options are: chemotherapy (docetaxel, cabazitaxel) and new hormonal agents (abiraterone acetate, enzalutamid). The paper presents perennial natural history of prostate cancer in the patient treated with all above mentioned therapeutic methods. For the last two years the patient has recieved abiraterone acetate, which was well tolerated, with the effect of disease stabilization and quality of life improvement.

Abstract

Prostate cancer is the second most frequently diagnosed cancer of men in Poland. There are two well-established primary therapeutic modalities to manage patients with early and locally advanced prostate cancer: surgical treatment and radiotherapy. Hormonal therapy is mainly used in advanced disease. The state of castration-resistant prostate cancer remains still the main therapeutic challenge. In this clinical scenario available therapeutic options are: chemotherapy (docetaxel, cabazitaxel) and new hormonal agents (abiraterone acetate, enzalutamid). The paper presents perennial natural history of prostate cancer in the patient treated with all above mentioned therapeutic methods. For the last two years the patient has recieved abiraterone acetate, which was well tolerated, with the effect of disease stabilization and quality of life improvement.

Get Citation

Keywords

prostate cancer, castration resistance, CRPC, abiraterone acetate

About this article
Title

The perennial natural history of castration-resistant prostate cancer in the patient treated with docetaxel, cabazitaxel and abiraterone acetate

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. C (2014)

Article type

Case report

Pages

12-15

Published online

2014-08-29

Keywords

prostate cancer
castration resistance
CRPC
abiraterone acetate

Authors

Anna Wrona
Elżbieta Senkus-Konefka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl